import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "semaglutide-vs-ozempic-vs-wegovy-complete-guide-2026",
  title: "Semaglutide vs. Ozempic vs. Wegovy: What Researchers Need to Know (2026)",
  description:
    "Ozempic, Wegovy, and research-grade semaglutide are all the same molecule — but with key differences in formulation, dosing, regulatory status, and research applications. This guide clarifies the distinctions.",
  category: "Compound Profiles",
  readMinutes: 8,
  publishedAt: "2026-06-12",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Semaglutide has become one of the most discussed molecules in modern pharmacology. Marketed as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management, semaglutide is a GLP-1 receptor agonist with a robust clinical evidence base. For researchers working with research-grade peptides, understanding how pharmaceutical semaglutide differs from research compound semaglutide — and what the clinical trial data actually shows — is essential background for study design and literature interpretation.",
    },
    {
      type: "heading",
      text: "The Molecule: What Is Semaglutide?",
    },
    {
      type: "paragraph",
      text: "Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), sharing approximately 94% sequence homology with the endogenous hormone. Its key structural modifications — a C18 fatty diacid chain attached via a linker at lysine-34, and an aib amino acid substitution at position 8 — confer resistance to DPP-4 enzymatic degradation and enable albumin binding. The result is a half-life of approximately 7 days, enabling once-weekly subcutaneous dosing.",
    },
    {
      type: "list",
      items: [
        "Molecular weight: ~4,113 Da",
        "Mechanism: GLP-1 receptor agonism — increases insulin secretion, suppresses glucagon, delays gastric emptying, reduces appetite via central hypothalamic effects",
        "Half-life: ~7 days (subcutaneous), ~1 week (oral, reduced due to bioavailability)",
        "Trade names: Ozempic (0.5–2 mg/week sc), Wegovy (2.4 mg/week sc), Rybelsus (oral, 7–14 mg/day)",
      ],
    },
    {
      type: "heading",
      text: "Ozempic vs. Wegovy: Same Molecule, Different Indications",
    },
    {
      type: "paragraph",
      text: "Both Ozempic and Wegovy contain semaglutide. The distinction is entirely regulatory and dose-related:",
    },
    {
      type: "table",
      headers: ["Feature", "Ozempic", "Wegovy"],
      rows: [
        ["Manufacturer", "Novo Nordisk", "Novo Nordisk"],
        ["Active compound", "Semaglutide", "Semaglutide"],
        ["Approved indication", "Type 2 diabetes (glycemic control)", "Chronic weight management (BMI ≥30 or ≥27 with comorbidity)"],
        ["Dose range", "0.25 → 0.5 → 1 → 2 mg/week sc", "0.25 → 0.5 → 1 → 1.7 → 2.4 mg/week sc"],
        ["FDA approval year", "2017", "2021"],
        ["Pen device", "Ozempic FlexTouch pen", "Wegovy pen (different pen, higher dose cartridge)"],
      ],
    },
    {
      type: "paragraph",
      text: "The primary clinical difference is the maintenance dose: 2.4 mg/week for Wegovy vs. a maximum 2 mg/week for Ozempic. The SELECT trial (2023) and SURMOUNT-class data demonstrated that higher doses produce greater weight loss, explaining the separate approval for obesity management at the higher dose.",
    },
    {
      type: "heading",
      text: "Research-Grade Semaglutide: Key Distinctions",
    },
    {
      type: "paragraph",
      text: "Research-grade semaglutide is the same peptide sequence but differs from pharmaceutical products in several ways relevant to preclinical and in vitro research:",
    },
    {
      type: "list",
      items: [
        "Formulation: Research compound is typically lyophilized powder requiring reconstitution; pharmaceutical products are pre-formulated in pH-adjusted buffer with excipients optimized for SC injection",
        "Regulatory status: Research compounds are not FDA-approved medicines; they are sold for laboratory research purposes only",
        "Purity verification: Quality vendors provide HPLC (≥98%) and mass spec confirmation; pharmaceutical semaglutide undergoes GMP manufacturing with regulatory batch release testing",
        "Cost: Research-grade semaglutide is substantially less expensive per mg than pharmaceutical product, making it accessible for preclinical dose-ranging studies",
        "Excipients: Pharmaceutical formulations include disodium phosphate dihydrate, propylene glycol, phenol, water for injection; research compound is typically pure peptide in lyophilized form",
      ],
    },
    {
      type: "callout",
      text: "For researchers: The identical molecular structure means published pharmacokinetic and receptor-binding data from pharmaceutical semaglutide studies is directly applicable to research-grade compound interpretation.",
    },
    {
      type: "heading",
      text: "Key Clinical Trial Data",
    },
    {
      type: "subheading",
      text: "SUSTAIN Trials (Ozempic — Glycemic Control)",
    },
    {
      type: "paragraph",
      text: "The SUSTAIN program (1–10) established semaglutide's glycemic efficacy in T2DM. SUSTAIN-6 (n=3,297) demonstrated a 26% reduction in MACE (major adverse cardiovascular events) vs. placebo over 104 weeks, leading to a cardiovascular risk reduction label addition for Ozempic.",
    },
    {
      type: "subheading",
      text: "STEP Trials (Wegovy — Weight Loss)",
    },
    {
      type: "paragraph",
      text: "The STEP program defined semaglutide's weight loss profile. STEP 1 (n=1,961, non-diabetic adults) showed mean weight reduction of 14.9% at 68 weeks with 2.4 mg/week sc vs. 2.4% with placebo. STEP 2 included T2DM subjects and showed 9.6% weight loss. Approximately 69% of participants in STEP 1 achieved ≥10% weight reduction.",
    },
    {
      type: "subheading",
      text: "SELECT Trial (Cardiovascular in Obesity, Non-Diabetic)",
    },
    {
      type: "paragraph",
      text: "The SELECT trial (n=17,604) was a landmark 2023 study demonstrating a 20% reduction in MACE in obese, non-diabetic patients with established cardiovascular disease. This data drove the 2024 FDA label expansion for Wegovy for cardiovascular risk reduction, the first weight loss drug to receive this indication.",
    },
    {
      type: "heading",
      text: "Active Research Areas for Semaglutide (2026)",
    },
    {
      type: "list",
      items: [
        "Neurodegeneration: Multiple trials investigating semaglutide in Parkinson's disease (SPARK trial, n=178) and Alzheimer's disease preclinical models — GLP-1Rs are expressed in dopaminergic neurons and hippocampus",
        "MASH/NAFLD: Phase 3 ESSENCE trial evaluating semaglutide 2.4 mg for metabolic-associated steatohepatitis; Phase 2 data showed 59% NASH resolution without fibrosis worsening at 72 weeks",
        "CKD: FLOW trial (2024) demonstrated 24% reduction in kidney disease progression with semaglutide — first GLP-1 to show kidney-specific benefit in T2DM with CKD",
        "Addiction: Emerging preclinical and observational data on GLP-1 agonists reducing alcohol and substance use; mechanism under investigation via mesolimbic dopamine pathway",
        "Heart failure: STEP-HFpEF trial demonstrated improvements in HFpEF symptoms, exercise capacity, and inflammation markers with semaglutide 2.4 mg",
      ],
    },
    {
      type: "heading",
      text: "Practical Research Considerations",
    },
    {
      type: "subheading",
      text: "Dose Translation from Clinical to Preclinical",
    },
    {
      type: "paragraph",
      text: "Clinical doses (0.5–2.4 mg/week) do not translate directly to rodent research. Allometric scaling using the FDA's body surface area method typically converts human doses to rodent equivalents by a factor of approximately 12 (mouse) or 6 (rat). Published mouse studies commonly use 10–300 nmol/kg/day ranges for acute metabolic endpoints.",
    },
    {
      type: "subheading",
      text: "Reconstitution for Research",
    },
    {
      type: "paragraph",
      text: "Lyophilized research-grade semaglutide is typically reconstituted in bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline. The fatty acid chain makes semaglutide relatively hydrophobic; vortexing is not recommended — gentle swirling until fully dissolved. Reconstituted solutions should be stored at 4°C and used within 28 days.",
    },
    {
      type: "heading",
      text: "Sourcing Research-Grade Semaglutide",
    },
    {
      type: "paragraph",
      text: "Researchers sourcing semaglutide for preclinical work should verify third-party HPLC purity (≥98%), mass spectrometry confirmation of the exact molecular weight (~4,113 Da), and LAL endotoxin testing for injectable preparations. The fatty acid modification makes semaglutide a structurally complex peptide — quality differences between suppliers are meaningful.",
    },
    {
      type: "disclaimer",
      text: "This article is for informational and research purposes only. Pharmaceutical semaglutide (Ozempic, Wegovy) are FDA-approved medications available only by prescription. Research-grade semaglutide is a research compound not approved for human use. Consult a licensed physician for medical guidance.",
    },
  ],
};
